Author
Emma Donadieu
Founder & Managing Director
MSc
I’ve spent more than 20 years helping healthcare organisations translate complex science into effective communications. After completing a Master’s degree in Science Communication at Imperial College London, I built my career across healthcare advertising, medical communications and product management, working with global healthcare agencies as well as pharmaceutical and medical device companies. Having worked both agency-side and client-side, I’ve developed a practical understanding of the scientific, commercial and strategic challenges facing healthcare organisations.
Today, I’m the Founder and Managing Director of Elion Medical Communications, a boutique agency that partners with pharmaceutical, biotechnology, and medical device companies to deliver high-quality medical writing and healthcare communications. I founded Elion with the belief that better outcomes come from long-term partnerships with people who understand your business, your science, and your goals. By combining scientific expertise with a collaborative and responsive approach, we build trusted relationships and become a seamless extension of our clients’ teams.
Outside of work, you’ll usually find me exploring New Zealand’s outdoors with my family or caring for our ever-growing menagerie of animals.
Areas of interest
- Anaesthesia
- Metabolic diseases
- Oncology
- Respiratory medicine
- Women’s health
My Time
Publications I’ve worked on
- Lam KO, Li KH, Leung RC, Tang V, Yau T. Trifluridine/Tipiracil (FTD/TPI) in metastatic colorectal cancer in Hong Kong: a territory-wide cohort study. Adv Ther. 2025;42(2):1222-1236. doi:10.1007/s12325-024-03077-4
- Sheck L. DMO: looking beyond HbA1c. NZ Optics. Published April 11, 2024. Accessed June 17, 2026
- Kameda H, Tasaka S, Takahashi T, Suzuki K, Soeda N, Tanaka Y. Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: an interim analysis of a post-marketing surveillance. Mod Rheumatol. 2024;34(3):444-452. doi:10.1093/mr/road055
- Ishii T, Sato Y, Munakata Y, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: two single-dose studies. Mod Rheumatol. 2023;33(2):279-291. doi:10.1093/mr/roac036
- Masuda T, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: interim report of a phase I/II randomized controlled trial. Vaccine. 2022;40(24):3380-3388. doi:10.1016/j.vaccine.2022.04.035
- Masuda T, Murakami K, Sugiura K, Sakui S, Philip Schuring R, Mori M. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: an interim report. Vaccine. 2022;40(13):2044-2052. doi:10.1016/j.vaccine.2022.02.030
- Hida T, Nishino M, Yoh K, et al. A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients. Ann Oncol. 2021;32(suppl 5):S981. doi:10.1016/j.annonc.2021.08.1851
- Zhang S, Yin Y, Li Q, Zhang C. Comparison of cumulative live birth rates between GnRH-A and PPOS in low-prognosis patients according to POSEIDON criteria: acohort study. Front Endocrinol (Lausanne). 2021;12:644456. Published 2021 Jun 21. doi:10.3389/fendo.2021.644456
- Kimura Y, Yamaguchi S, Suzuki T, et al. Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain: a multi-center, prospective, single-arm, open-label study (MIROP Study). Pain Ther. 2021;10(1):711-727. doi:10.1007/s40122-021-00255-y
- Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37(25):2235-2245. doi:10.1200/JCO.19.00075
- Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14(8):1161-1172. doi:10.2215/CJN.14751218
- Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. The unique pharmacological and pharmacokinetic profile of teneligliptin: implications for clinical practice. Drugs. 2019;79(7):733-750. doi:10.1007/s40265-019-01086-0
- Adachi M, Hozawa S, Nishikawa M, Yoshida A, Jinnai T, Tamura G. Asthma control and quality of life in a real-life setting: a cross-sectional study of adult asthma patients in Japan (ACQUIRE-2). J Asthma. 2019;56(9):1016-1025. doi:10.1080/02770903.2018.1514628
- Watada H, Shiramoto M, Irie S, et al. G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients. J Diabetes Investig. 2019;10(1):84-93. doi:10.1111/jdi.12849
- Ohno Matsui K, Ikuno Y, Lai TYY, Cheung CMG. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018;63:92 106. doi:10.1016/j.preteyeres.2017.10.005
